Can Evecxia Therapeutics turn EVX-101 into the first serotonin synthesis amplification therapy?
EVX-101 revives serotonin synthesis as an SSRI add-on strategy. Can Evecxia prove old biology still has new clinical value?
Neurocrine Biosciences strengthens INGREZZA case with functional improvement data
Mild TD can still disrupt work and independence. Neurocrine’s INGREZZA data raises pressure to rethink when treatment begins.
Can Teva Pharmaceutical Industries Ltd.’s Home Ground platform reshape schizophrenia support beyond medication?
Read how Teva Pharmaceutical Industries Ltd.’s Home Ground may reshape schizophrenia support, adherence, and care pathways. Discover what changes next.